At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 685 enrolled
Drug / intervention
placebo to match albiglutide +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating placebo to match albiglutide, albiglutide, and 4 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 685 participants across 358 sites in 9 countries.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany, Hong Kong, India, Peru, Philippines, Russia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedFeb 2009
Primary CompletionJan 2012
Study CompletionApr 2013
TodayJul 2026
First PostedFeb 9, 2009
Enrollment StartFeb 1, 2009
Primary CompletionJan 1, 2012
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.4 years ago
Interventions
placebo to match albiglutidedrug
albiglutide matching placebo weekly subcutaneous injection
albiglutidebiological
albiglutide weekly subcutaneous injection
metformindrug
metformin
glimepiridedrug
glimepiride
pioglitazonedrug
pioglitazone
placebo to match pioglitazonedrug
pioglitazone matching placebo